Ertugliflozin: Cardioprotective Effects on Epicardial Fat

Trial ID or NCT#

NCT04167761

Status

not recruiting iconNOT RECRUITING

Purpose

The purpose of this study is to learn if Sodium-Glucose Cotransporter 2 inhibitor (SGLT2i) medications enhance beneficial properties of epicardial adipose tissue including metabolic flexibility, insulin sensitivity, decreased cell size and reduced inflammation.

Official Title

Ertugliflozin: Cardioprotective Effects on Epicardial Fat

Eligibility Criteria

Ages Eligible for Study: 18 Years to 80 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - patient at Stanford Cardiovascular Surgery clinic who is scheduled for cardiac bypass surgery - history of Diabetes Mellitus Type 2 currently taking metformin or diet-controlled
Exclusion Criteria:
  1. - allergy or intolerance to interventional medication - currently taking any anti-diabetic medication other than metformin
View All Criteria
Show Less

Investigator(s)

Tracey McLaughlin
Tracey McLaughlin
Endocrinologist
Professor of Medicine (Endocrinology)

Contact us to find out if this trial is right for you.

Contact

Tracey McLaughlin, MD
650-736-2056

View on ClinicalTrials.gov